1-2 of 2
Vikas Joshi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety Profile of Crizanlizumab 5.0 Mg/Kg in Sickle Cell Disease: Pooled Data from Clinical Trials

Abdullah Kutlar, Vikas Joshi, Andreas Brueckner, Julie Kanter, Darla K. Liles, Jeremie Lincy, Rahul Manjare, Yvonne Dei Adomakoh, Matthew M. Heeney, Mariane de Montalembert, Deborah Keefe, Kwaku Marfo, Kenneth I. Ataga
Journal: Blood
Blood (2023) 142 (Supplement 1): 1139.
https://doi.org/10.1182/blood-2023-188639
Published: 2023
Journal Articles

Rare Cases of Infusion-Related Reactions (IRRs) Presenting As Pain Events during or after Crizanlizumab Infusion in Patients (Pts) with Sickle Cell Disease (SCD): A Systematic Evaluation of Post-Marketing (PM) Reports

Julie Kanter, Amit Shah, Vikas Joshi, Harshit Mehta, Michael Levine, Uma Arunagiri, Jincy Paulose, Breanne Donohue, Alissa Scalera, Deepa Manwani
Journal: Blood
Blood (2021) 138 (Supplement 1): 3112.
https://doi.org/10.1182/blood-2021-152362
Published: 2021